Home › Urogenital Cancer › Ohio
Urogenital Cancer clinical trials in Ohio
6 studies for Urogenital Cancer are looking for participants at sites in Ohio.
Cities in Ohio
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
- Strecker Cancer Center-Belpre, Belpre
- Adena Regional Medical Center, Chillicothe
- Ohio State University Comprehensive Cancer Center, Columbus
- and 22 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT03866382Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)
- Oncology Hematology Care Clinical Trials, LLC, Fairfield
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 28, 2026 · NCT07566156A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001)
- The Ohio State University Comprehensive Cancer Center, Columbus
RecruitingPhase 1
Ages 18 and older · Men · Updated Oct 20, 2026 · NCT07103018uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto
- Ohio State University, Columbus
RecruitingObservational study
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT05874921A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
- The Ohio State University Comprehensive Cancer Center, Columbus
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 11, 2026 · NCT05592626Feasibility Study of CBCT for IGRT in Cancer Patients
- James Outpatient Center, Columbus
- Ohio State University, Brain and Spine Hospital, Columbus
- The Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Columbus
- and 1 more
Recruiting
Ages 18 and older · All sexes · Updated Mar 13, 2026 · NCT06681233From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.